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Available online 27 November 2014The accurate quantiﬁcation of selenoprotein P (SePP) is of
growing interest for basic research and clinical studies in a
variety of areas. Currently, there is some discrepancy on
SePP concentrations in humans. Two major reasons con-
tribute to this inconsistency; the characterization and
validation of some (even commercial) SePP assays is mar-
ginal or missing and there is no uniform reference material
for standardization.
Out of the need to compare clinical results across research
groups we decided to develop a monoclonal antibody-based
enzyme immunoassay according to highest standards of
laboratory-developed molecular assays suitable for 96-well
analysis (DeSilva et al., 2003). The assay procedure is optimized
to follow a standard enzyme-linked immunoassay protocol and
uses a chromogenic detection method available in most labora-
tories. The assay standard curve is calibrated against NIST SRM
1950 standard reference plasma (Ballihaut et al., 2011, 2012).
Multi-laboratory validation tests were performed according
to international guidelines (FDA, 2001). The accuracy was
measured with an average deviation from the true0.1016/j.pisc.2014.11.013
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utz.schomburg@charite.de (L. Schomburg).concentration of +2.9% RE. Precision was determined at three
levels: repeatability (with-in plate variation), intermediate
precision (within-laboratories variation), and reproducibility
(between-laboratories variation), with coefﬁcients-of-
variation (CV) each below 15%. The limit of quantitation was
less than 10 mg/l, i.e., around 500-fold below average serum
SePP concentrations of well-supplied subjects. The signals
were linear on dilution within the working range of the assay,
and SePP was stable in serum for 24 h at room temperature.
The analytical performance characteristics of this ELISA
indicate that it is suitable to provide comparable results for
multi-laboratory studies with clinical samples. We have thus
decided to make this assay commercially available in order
to support research on Se and SePP status across the
different research and clinical disciplines.
In our ﬁrst measurements using this test more than ten
thousand samples have been analyzed. These measurements
showed high precision and reproducibility and generated
the data needed for risk analysis of colorectal cancer in
Western Europeans, which proved to be increased in
individuals with relatively low Se status (Hughes et al.,
2014), Epub ahead of print.
In summary, the newly developed SePP ELISA based on
monoclonal antibodies represents a highly accurate and
reproducible quantiﬁcation of SePP from human body ﬂuids
and cell culture experiments. We assume that this novelrticle under the CC BY-NC-ND license
S. Hybsier et al.24in vitro assay system will prove of high value for future
experiments aiming to elucidate the importance of the Se
status and selenoproteins in human health and disease.Conﬂict of interest
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